BLFS Overview

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is33.25 USD with a low forecast of 32.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BioLife Solutions Inc revenue for the last quarter amounts to 18.79M USD, increased 24.34

BioLife Solutions Inc. EPS for the last quarter amounts to 0.23 USD, decreased -14.81

BioLife Solutions Inc (BLFS) has 155 emplpoyees as of March 11 2026.

Today BLFS has the market capitalization of 901.76M USD.